Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib1, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform
Opaganib EVD rationale (analogous to EVD treatment pathway):234®
6Opaganib, an investigational SPHK2 inhibitor drug, offers a novel potential approach to strengthen global infectious disease preparedness and biodefense:The Company has provided available supply readiness, safety and efficacy data to aid rapid discussions to enable clinical exploration of the potential synergies of opaganib host-directed therapy in addressing a growing global public health threat
TEL AVIV, Israel and RALEIGH, N.C., June 3, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it is actively discussing potential collaborations for advancement of its investigational oral drug, opaganib, to combat EVD, which can be fatal in approximately half of all cases7, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform and pharma collaborations.
